Rebecca Andrews
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rebecca Andrews has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Amir Qaseem
American College of Physicians, Philadelphia, Pennsylvania
5 shared publications Linda L. Humphrey
Oregon Health & Science University, Portland, Oregon (L.L.H.).
5 shared publications- George M. Abraham
University of Massachusetts Medical School and Saint Vincent Hospital, Worcester, Massachusetts (G.M.A.)
4 shared publications - Janet A. Jokela
University of Illinois College of Medicine at Urbana-Champaign, Champaign, Illinois (J.A.J.)
4 shared publications - Matthew C. Miller
Penn Medicine, Philadelphia, Pennsylvania
4 shared publications Sameer D. Saini
4 shared publications
Latest Publications
- 1 October 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (10) , 1524
Quality Indicators for Diabetes in Adults
- 1 October 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (10) , 1524
Quality Indicators for Diabetes in Adults
- 1 April 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (4) , 559-563
Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3)
The American College of Physicians (ACP) maintains living, rapid practice points on antiviral treatment in the outpatient setting for COVID-19. The Population Health and Medical Science Committee (PHMSC) developed this version 3 based on evidence from a focused update of a living, rapid review conducted by the ACP Center for Evidence Reviews at Cochrane Austria. This version addresses the SARS-CoV-2 Omicron variant and reaffirms previous practice points on the use of antiviral treatments of confirmed COVID-19 in unvaccinated or vaccinated and symptomatic patients in the outpatient setting. Consider nirmatrelvir-ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. The PHMSC is retiring this topic from living status considering that this update and previous surveillance have not yielded important changes to the practice points.
- 1 April 2026
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 179 (4) , 559-563
Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3)
The American College of Physicians (ACP) maintains living, rapid practice points on antiviral treatment in the outpatient setting for COVID-19. The Population Health and Medical Science Committee (PHMSC) developed this version 3 based on evidence from a focused update of a living, rapid review conducted by the ACP Center for Evidence Reviews at Cochrane Austria. This version addresses the SARS-CoV-2 Omicron variant and reaffirms previous practice points on the use of antiviral treatments of confirmed COVID-19 in unvaccinated or vaccinated and symptomatic patients in the outpatient setting. Consider nirmatrelvir-ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. The PHMSC is retiring this topic from living status considering that this update and previous surveillance have not yielded important changes to the practice points.
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1653-1654
Deja Flu All Over Again: The Risk for Overwhelm of the U.S. Health Care System by Vaccine-Preventable and Modifiable Diseases
- 1 November 2025
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 178 (11) , 1653-1654
Deja Flu All Over Again: The Risk for Overwhelm of the U.S. Health Care System by Vaccine-Preventable and Modifiable Diseases
- 1 April 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (4) , 507-513
Quality Indicators for Major Depressive Disorder in Adults: A Review of Performance Measures by the American College of Physicians
Major depressive disorder (MDD) is a severe mood disorder that affects at least 8.4% of the adult population in the United States. Characteristics of MDD include persistent sadness, diminished interest in daily activities, and a state of hopelessness. The illness may progress quickly and have devastating consequences if left untreated. Eight performance measures are available to evaluate screening, diagnosis, and successful management of MDD. However, many performance measures do not meet the criteria for validity, reliability, evidence, and meaningfulness. The American College of Physicians (ACP) embraces performance measurement as a means to externally validate the quality of care of practices, medical groups, and health plans and to drive reimbursement processes. However, a plethora of performance measures that provide low or no value to patient care have inundated physicians, practices, and systems and burdened them with collecting and reporting of data. The ACP's Performance Measurement Committee (PMC) reviews performance measures using a validated process to inform regulatory and accreditation bodies in an effort to recognize high-quality performance measures, address gaps and areas for improvement in performance measures, and help reduce reporting burden. Out of 8 performance measures, the PMC found only 1 measure (suicide risk assessment) that was valid at all levels of attribution. This paper presents a review of MDD performance measures and highlights opportunities to improve performance measures addressing MDD management.
- 1 April 2024
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 177 (4) , 507-513
Quality Indicators for Major Depressive Disorder in Adults: A Review of Performance Measures by the American College of Physicians
Major depressive disorder (MDD) is a severe mood disorder that affects at least 8.4% of the adult population in the United States. Characteristics of MDD include persistent sadness, diminished interest in daily activities, and a state of hopelessness. The illness may progress quickly and have devastating consequences if left untreated. Eight performance measures are available to evaluate screening, diagnosis, and successful management of MDD. However, many performance measures do not meet the criteria for validity, reliability, evidence, and meaningfulness. The American College of Physicians (ACP) embraces performance measurement as a means to externally validate the quality of care of practices, medical groups, and health plans and to drive reimbursement processes. However, a plethora of performance measures that provide low or no value to patient care have inundated physicians, practices, and systems and burdened them with collecting and reporting of data. The ACP's Performance Measurement Committee (PMC) reviews performance measures using a validated process to inform regulatory and accreditation bodies in an effort to recognize high-quality performance measures, address gaps and areas for improvement in performance measures, and help reduce reporting burden. Out of 8 performance measures, the PMC found only 1 measure (suicide risk assessment) that was valid at all levels of attribution. This paper presents a review of MDD performance measures and highlights opportunities to improve performance measures addressing MDD management.
- 1 October 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (10) , 1396-1404
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2)
Evidence for the use of outpatient treatments in adults with confirmed COVID-19 continues to evolve with new data. This is version 2 of the American College of Physicians (ACP) living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically addressing the dominant SARS-CoV-2 Omicron variant. The Population Health and Medical Science Committee (formerly the Scientific Medical Policy Committee) developed this version of the living, rapid practice points on the basis of a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems (Danube University Krems). This topic will be maintained as living and rapid by continually monitoring and assessing the impact of new evidence. Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Consider nirmatrelvir-ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
- 1 October 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (10) , 1396-1404
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2)
Evidence for the use of outpatient treatments in adults with confirmed COVID-19 continues to evolve with new data. This is version 2 of the American College of Physicians (ACP) living, rapid practice points focusing on 22 outpatient treatments for COVID-19, specifically addressing the dominant SARS-CoV-2 Omicron variant. The Population Health and Medical Science Committee (formerly the Scientific Medical Policy Committee) developed this version of the living, rapid practice points on the basis of a living, rapid review done by the ACP Center for Evidence Reviews at Cochrane Austria at the University for Continuing Education Krems (Danube University Krems). This topic will be maintained as living and rapid by continually monitoring and assessing the impact of new evidence. Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Consider nirmatrelvir-ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease. Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting. Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
- 1 February 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (2) , eA220003
Annals On Call - Outpatient Treatment of COVID-19
- 1 February 2023
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (2) , eA220003
Annals On Call - Outpatient Treatment of COVID-19
- 29 November 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (1) , 115-124
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)
The Scientific Medical Policy Committee of the American College of Physicians (ACP) developed living, rapid practice points to summarize the best available evidence on the treatment of adults with ... Description: Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data emerge on SARS-CoV-2 variants and the availability of newer treatments. The Scientific Medical Po...
- 29 November 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 176 (1) , 115-124
Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1)
The Scientific Medical Policy Committee of the American College of Physicians (ACP) developed living, rapid practice points to summarize the best available evidence on the treatment of adults with ... Description: Strategies to manage COVID-19 in the outpatient setting continue to evolve as new data emerge on SARS-CoV-2 variants and the availability of newer treatments. The Scientific Medical Po...
- Open Access
- 1 June 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (6) , 822-827
Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians
This ACP guideline describes best practices for prescribing appropriate and short-duration antibiotic therapy for patients presenting with acute bronchitis with chronic obstructive pulmonary diseas... Description: Antimicrobial overuse is a major health care issue that contributes to antibiotic resistance. Such overuse includes unnecessarily long durations of antibiotic therapy in patients with ...
- 1 June 2021
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 174 (6) , 822-827
Open AccessAppropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians
This ACP guideline describes best practices for prescribing appropriate and short-duration antibiotic therapy for patients presenting with acute bronchitis with chronic obstructive pulmonary diseas... Description: Antimicrobial overuse is a major health care issue that contributes to antibiotic resistance. Such overuse includes unnecessarily long durations of antibiotic therapy in patients with ...
- 1 January 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (1) , 116-118
Prophylactic antibiotics prior to dental procedures: A cross-disciplinary survey of dentists and medical providers
- 1 January 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (1) , 116-118
Prophylactic antibiotics prior to dental procedures: A cross-disciplinary survey of dentists and medical providers